<DOC>
	<DOC>NCT01072968</DOC>
	<brief_summary>Multicenter randomized double blind study versus placebo during 12 weeks with at first, an escalating dose period followed by stable dose period at the selected dose. This double-blind period can be followed by a 9 months open-label period if the patient wishes to continue with the study product.</brief_summary>
	<brief_title>BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP.</brief_title>
	<detailed_description>The first period (12 weeks double blind period) will aim at demonstrating the efficacy and safety of BF2.649 by verifying whether the results of BF2.649 are superior to those of placebo. The aim of the second period (open label extension phase) will be to assess the long-term tolerance, as well as the maintenance of the BF2.649 efficacy.</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea, Obstructive</mesh_term>
	<criteria>Patients with OSA still complaining EDS,refusing nCPAP ESS score â‰¥ 12 Patients suffering from insomnia without OSA Coexisting narcolepsy Patient with sleep debt not due to OSA Acute or chronic severe disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Multicenter</keyword>
	<keyword>Randomized</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Efficacy and safety study</keyword>
	<keyword>BF2.649 versus placebo</keyword>
	<keyword>Patients suffering from Obstructive Sleep Apnea</keyword>
	<keyword>Complaining from Excessive Daytime Sleepiness</keyword>
	<keyword>Refusing nasal Continuous Positive Airway Pressure</keyword>
</DOC>